Orexigen Gets $22M From Partners

San Diego-based biopharmaceuticals developer Orexigen Therapeutics, which is developing treatments for obesity, reported receiving a total of $22M from two different partners. Orexigen ssaid it hass received $15M from partner Takeda Pharmaceuticals, the first of three milestone payments to the company, and $7M from Kwang Dong Pharmaceutical Company Ltd.. Both companies are partnered with Orexigen on marketing and other efforts. Orexigen is led by CEO Mike Narachi.